M&Z Helps Secure Regulatory Reform on Test Data Exclusivity for New Medicines in Ecuador
Updated: Oct 5
On March 10, 2025, an amendment to Resolution ARCSA-DE-2024-023-DASP was published in Ecuador’s Official Register. The Resolution governs test data exclusivity for pharmaceutical products containing new chemical entities. The amendment marks an important development for the pharmaceutical industry by protecting investment in the research and development of new medicines in Ecuador.
Background and Challenges Under the Previous Regulations
The original regulations, issued by ARCSA on June 28, 2024, contained a complex definition of “new chemical entity.” That definition was inconsistent with Andean Community Decision 486 and the Organic Code on the Social Economy of Knowledge, Creativity and Innovation (the Ingenios Code). These legal instruments provide a framework for protecting pharmaceutical intellectual property and promoting innovation.
New chemical entity. A medicine, ingredient or active substance for human use or consumption that has never been used for any therapeutic indication anywhere in the world. The term excludes, among other things, new or second uses, as well as innovations or changes relating to pharmaceutical forms, indications or second indications, new combinations of known chemical entities, formulations, dosage forms, routes of administration, modifications of any kind that do not affect the mechanism of action, marketing and packaging conditions and, generally, changes involving new product presentations.
Meythaler & Zambrano Abogados’ Key Role
Through Meythaler & Zambrano Abogados’ active involvement and timely intervention, ARCSA submitted a legal inquiry to Ecuador’s Office of the Attorney General. The resulting binding legal opinion concluded that, when defining “new chemical entity,” ARCSA:
“must apply the relevant provisions of the Organic Code on the Social Economy of Knowledge, Creativity and Innovation, ensuring consistency with the international instruments ratified by Ecuador on this subject.”
M&Z’s intervention was instrumental in aligning the regulations with domestic and international legal standards.
Revised Definition of New Chemical Entity
As a result of this specialized legal work, ARCSA amended the definition in Chapter II of the Resolution on February 10, 2025, adopting the following wording:
New chemical entity. A medicine, ingredient or active substance for human use or consumption that has not previously been approved in Ecuador.
The revised definition provides greater clarity and enables new medicines to qualify for test data exclusivity, protecting investment in pharmaceutical innovation.
Benefits for the Pharmaceutical Industry
Protection of innovation: The amendment provides pharmaceutical companies with a period of test data exclusivity, encouraging investment in research and development.
Regulatory alignment: It brings the regulations into line with international standards and domestic legislation, strengthening Ecuador’s regulatory framework.
Support for pharmaceutical development: The clearer definition facilitates the registration of new medicines and supports the industry’s growth.
Our Commitment to Protecting Pharmaceutical Innovation
Meythaler & Zambrano Abogados played a key role in securing this regulatory reform. This achievement reflects our commitment to delivering high-quality legal advice, protecting our clients’ investment in research and development, and helping shape a regulatory environment that supports pharmaceutical innovation in Ecuador.
The amendment represents a significant step forward for Ecuador’s pharmaceutical industry, bringing its regulatory framework into line with international standards and supporting the development of new medicines.
Contact Meythaler & Zambrano Abogados to explore how Ecuador’s test data exclusivity framework can help protect your pharmaceutical portfolio and investment in innovation.
